Oryzon Genomics S.A.
ORY | MC
Overview
Corporate Details
- ISIN(s):
- ES0167733015
- LEI:
- 95980063R15RDF29DK13
- Country:
- Spain
- Address:
- Sant Ferran 74, 08940 Cornellà de Llobregat
- Website:
- https://www.oryzon.com/en
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Founded in 2000 in Barcelona, Spain, Oryzon is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds Vafidemstat and Iadademstat in Phase II clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-26 08:04 |
General Meeting Notice
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S…
|
Spanish | 139.0 KB | |
| 2025-05-26 00:00 |
General Meeting Notice
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S…
|
Spanish | 139.0 KB | |
| 2025-05-12 07:52 |
Regulatory News Service
La sociedad remite información sobre los resultados del primer trimestre de 2025
|
Spanish | 370.8 KB | |
| 2025-05-08 08:06 |
Regulatory News Service
ORYZON recibe una ayuda no reembolsable de 13,26 millones de € para su proyecto…
|
Spanish | 250.1 KB | |
| 2025-04-29 00:00 |
Directors' Dealings
Motivo de la notificación: Persona con Responsabilidad de Dirección
|
Spanish | 91.4 KB | |
| 2025-04-25 13:52 |
Regulatory News Service
Se comunica la inscripción en el Registro mercantil de la escritura de ampliaci…
|
Spanish | 202.4 KB | |
| 2025-04-24 08:13 |
Inside Information Statement
Resultado de la colocación acelerada
|
Spanish | 178.7 KB | |
| 2025-04-23 18:34 |
Inside Information Statement
Lanzamiento de ampliación de capital acelerada
|
Spanish | 195.2 KB | |
| 2025-04-23 17:58 |
Share Issue/Capital Change
Lanzamiento de ampliación de capital acelerada
|
Spanish | 195.2 KB | |
| 2025-02-28 14:54 |
Declaration of Voting Results & Voting Rights Announcements
ORYZON anuncia los resultados de la votación de su Junta General Extraordinaria…
|
Spanish | 51.6 KB | |
| 2025-02-28 00:00 |
Declaration of Voting Results & Voting Rights Announcements
ORYZON anuncia los resultados de la votación de su Junta General Extraordinaria…
|
Spanish | 55.0 KB | |
| 2025-02-27 19:03 |
Regulatory News Service
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del …
|
Spanish | 189.1 KB | |
| 2025-02-27 18:57 |
Declaration of Voting Results & Voting Rights Announcements
La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2024
|
Spanish | 437.0 KB | |
| 2025-02-27 00:00 |
Annual Audited Financial Statements
|
Spanish | 13.7 MB | |
| 2025-01-25 17:32 |
Regulatory News Service
Convocatoria de la Junta General Extraordinaria de accionistas de Oryzon Genomi…
|
Spanish | 202.6 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |